Mycobacterial Diseases
Open Access

Pathophysiology of Musculoskeletal Tuberculosis and its Prevention Measures

Sahim Nawaz^{* *}Correspondence: Sahim Nawaz, Department of Bacteriology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana, Email:

Author info »

Description

Musculoskeletal Tuberculosis (TB) is a form of tuberculosis that affects the bones, joints, and muscles. Although TB primarily affects the lungs, it can spread to other parts of the body, including the musculoskeletal system. This form of TB is relatively uncommon but can lead to significant morbidity if not diagnosed and treated promptly. In this article, we will explore the causes, symptoms, diagnosis, and treatment options for musculoskeletal TB, shedding light on this silent but debilitating menace.

Understanding musculoskeletal tuberculosis

Musculoskeletal TB occurs when the bacteria responsible for tuberculosis, Mycobacterium tuberculosis, infiltrates the musculoskeletal system. This can happen through the bloodstream from the primary site of infection, typically the lungs, or through direct spread from an adjacent infected tissue [1]. Individuals with compromised immune systems, such as those living with HIV/AIDS, are at a higher risk of developing musculoskeletal TB.

Symptoms and clinical presentation

The symptoms of musculoskeletal TB can vary depending on the affected site, but the most common complaints include pain, swelling, and limited joint movement [2]. The onset of symptoms is often insidious and can be mistaken for other musculoskeletal conditions, leading to delayed diagnosis and treatment [3]. Furthermore, the symptoms may be intermittent, further adding to the diagnostic challenges. The most frequently affected sites include the spine, hip, knee, and ankle joints. Spinal TB, also known as Pott's disease, is the most common form of musculoskeletal TB [4]. It can lead to spinal deformities, abscess formation, and neurologic complications if left untreated.

Diagnosis

Diagnosing musculoskeletal TB can be challenging, as the initial symptoms may be nonspecific and mimic other conditions. A through clinical evaluation, including a detailed medical history and physical examination, is essential [5]. The presence of risk factors, such as a history of TB exposure or immunosuppression, should raise suspicion for musculoskeletal TB. Radiological imaging plays a crucial role in the diagnosis of musculoskeletal TB. X-rays, CT scans, and MRI scans can reveal characteristic findings such as lytic lesions, joint destruction, bone collapse, and abscess formation [6,7]. In some cases, a biopsy may be necessary to confirm the diagnosis by isolating the Mycobacterium tuberculosis bacteria.

Treatment

Treating musculoskeletal TB requires a multidrug regimen consisting of several anti-tuberculosis medications. The standard treatment protocol typically involves a combination of isoniazid, rifampicin, pyrazinamide, and ethambutol [8]. These medications are administered for an extended duration, typically six to twelve months, to ensure complete eradication of the bacteria. In cases where there is a significant deformity or abscess formation, surgical intervention may be necessary. Surgical procedures can involve debridement of infected tissue, stabilization of affected bones, and abscess drainage. Physical therapy is often recommended after treatment to restore joint function and strengthen the affected area [9].

Prevention and control

Preventing the spread of musculoskeletal TB involves addressing the primary source of infection. Effective control measures for tuberculosis, such as early detection, prompt treatment, and contact tracing, are crucial in preventing the development of musculoskeletal TB. Additionally, promoting overall community awareness about tuberculosis and its consequences can help reduce the burden of this disease [10].

Conclusion

Musculoskeletal tuberculosis, although relatively rare, can have severe consequences if not diagnosed and treated in a timely manner. The insidious onset of symptoms, the potential for misdiagnosis, and the risk of complications make it imperative to maintain a high index of suspicion in patients with risk factors. A comprehensive approach involving clinical evaluation, radiological imaging, and targeted treatment is necessary to effectively manage.

References

1. Dorjravdan M, Kouda K, Boldoo T, Dambaa N, Sovd T, Nakama C, et al. Association between household solid fuel use and tuberculosis: Cross-sectional data from the Mongolian National Tuberculosis Prevalence Survey. Environ Health Prev Med. 2021;26(1):76.

   [Crossref] [Google Scholar] [Pubmed]

2. Poh XY, Hong JM, Bai C, Miow QH, Thong PM, Wang Y, et al. Nos2-/-mice infected with M. tuberculosis develop neurobehavioral changes and immunopathology mimicking human central nervous system tuberculosis. J Neuroinflammation. 2022;19(1):21.

   [Crossref] [Google Scholar] [Pubmed]

3. Martin C, Walker B. Attenuated strains of Mycobacterium tuberculosis complex for laboratory and clinical use. Tuberculosis (Edinb). 2008;88(5):371-374.

   [Crossref] [Google Scholar][Pubmed]

4. Jackson M, Phalen SW, Lagranderie M, Ensergueix D, Chavarot P, Marchal G, et al. Persistence and protective efficacy of a Mycobacterium tuberculosis auxotroph vaccine. Infect Immun. 1999;67(6):2867-2873.

   [Crossref] [Google Scholar] [Pubmed]

5. Sambandamurthy VK, Wang X, Chen B, Russell RG, Derrick S, Collins FM, et al. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med. 2002;8(10):1171-1174.

   [Crossref] [Google Scholar] [Pubmed]

6. Sambandamurthy VK, Derrick SC, Jalapathy KV, Chen B, Russell RG, Morris SL, et al. Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect Immun. 2005;73(2):1196-1203.

   [Crossref] [Google Scholar] [Pubmed]

7. Sampson SL, Mansfield KG, Carville A, Magee DM, Quitugua T, Howerth EW, et al. Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate. Vaccine. 2011;29(29-30):4839-4847.

   [Crossref] [Google Scholar] [Pubmed]

8. Hinchey J, Jeon BY, Alley H, Chen B, Goldberg M, Derrick S, et al. Lysine auxotrophy combined with deletion of the SecA2 gene results in a safe and highly immunogenic candidate live attenuated vaccine for tuberculosis. PLoS One. 2011;6(1):e15857.

   [Crossref] [Google Scholar] [Pubmed]

9. Arbues A, Aguilo JI, Gonzalo-Asensio J, Marinova D, Uranga S, Puentes E, et al. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine. 2013;31(42):4867-4873.

   [Crossref] [Google Scholar] [Pubmed]

10. Walker KB, Brennan MJ, Ho MM, Eskola J, Thiry G, Sadoff J, et al. The second Geneva Consensus: Recommendations for novel live TB vaccines. Vaccine. 2010;28(11):2259-2270.

    [Crossref] [Google Scholar] [Pubmed]